{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:15:44Z","timestamp":1769087744689,"version":"3.49.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1097\/hjh.0b013e32832f0ce4","type":"journal-article","created":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T06:57:34Z","timestamp":1267081054000},"page":"2094-2107","source":"Crossref","is-referenced-by-count":24,"title":["Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rats"],"prefix":"10.1097","volume":"27","author":[{"given":"Marjut","family":"Louhelainen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Vahtola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Forsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saara","family":"Merasto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ville","family":"Kyt\u00f6","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piet","family":"Finckenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Leskinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petri","family":"Kaheinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilkka","family":"Tikkanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jouko","family":"Levijoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eero","family":"Mervaala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-25-20210208","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2796.2001.00789.x","article-title":"Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention","volume":"249","author":"Laakso","year":"2001","journal-title":"J Intern Med"},{"key":"R2-25-20210208","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bmj.38678.389583.7C","article-title":"Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies","volume":"332","author":"Huxley","year":"2006","journal-title":"BMJ"},{"key":"R3-25-20210208","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/01.HYP.0000082814.62655.85","article-title":"AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase","volume":"42","author":"Privratsky","year":"2003","journal-title":"Hypertension"},{"key":"R4-25-20210208","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1210\/er.2003-0012","article-title":"Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications","volume":"25","author":"Fang","year":"2004","journal-title":"Endocr Rev"},{"key":"R5-25-20210208","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0140-6736(06)68074-4","article-title":"Controversies in ventricular remodelling","volume":"367","author":"Opie","year":"2006","journal-title":"Lancet"},{"key":"R6-25-20210208","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1172\/JCI24159","article-title":"Altered intracellular Ca2+ handling in heart failure","volume":"115","author":"Yano","year":"2005","journal-title":"J Clin Invest"},{"key":"R7-25-20210208","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/415198a","article-title":"Cardiac excitation-contraction coupling","volume":"415","author":"Bers","year":"2002","journal-title":"Nature"},{"key":"R8-25-20210208","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1006\/jmcc.2002.2037","article-title":"Calcium cycling in congestive heart failure","volume":"34","author":"Hasenfuss","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"R9-25-20210208","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.2165\/00003495-200363230-00009","article-title":"Levosimendan: a review of its use in the management of acute decompensated heart failure","volume":"63","author":"Innes","year":"2003","journal-title":"Drugs"},{"key":"R10-25-20210208","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/0022-2828(95)90009-8","article-title":"Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan","volume":"27","author":"Haikala","year":"1995","journal-title":"J Mol Cell Cardiol"},{"key":"R11-25-20210208","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00005344-200104000-00003","article-title":"Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels","volume":"37","author":"Kaheinen","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"R12-25-20210208","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1161\/01.CIR.102.18.2222","article-title":"Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators","volume":"102","author":"Slawsky","year":"2000","journal-title":"Circulation"},{"key":"R13-25-20210208","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/01.CIR.0000043245.00859.11","article-title":"Sustained hemodynamic effects of intravenous levosimendan","volume":"107","author":"Kivikko","year":"2003","journal-title":"Circulation"},{"key":"R14-25-20210208","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"R15-25-20210208","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"R16-25-20210208","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/sj.bjp.0707157","article-title":"Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl\/Rapp rats","volume":"150","author":"Louhelainen","year":"2007","journal-title":"Br J Pharmacol"},{"key":"R17-25-20210208","doi-asserted-by":"crossref","first-page":"26G","DOI":"10.1016\/j.amjcard.2005.07.018","article-title":"Cardioprotection: a new paradigm in the management of acute heart failure syndromes","volume":"96","author":"Maytin","year":"2005","journal-title":"Am J Cardiol"},{"key":"R18-25-20210208","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.amjcard.2005.03.092","article-title":"Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure","volume":"96","author":"Parissis","year":"2005","journal-title":"Am J Cardiol"},{"key":"R19-25-20210208","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1620\/tjem.119.85","article-title":"Production of spontaneous diabetic rats by repetition of selective breeding","volume":"119","author":"Goto","year":"1976","journal-title":"Tohoku J Exp Med"},{"key":"R20-25-20210208","doi-asserted-by":"crossref","first-page":"H2726","DOI":"10.1152\/ajpheart.2001.280.6.H2726","article-title":"Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats","volume":"280","author":"Palojoki","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R21-25-20210208","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0014-2999(01)00997-9","article-title":"Improved survival with simendan after experimental myocardial infarction in rats","volume":"419","author":"Levijoki","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"R22-25-20210208","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/0091270002042001005","article-title":"Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure","volume":"42","author":"Kivikko","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R23-25-20210208","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/HJH.0b013e3282f293c8","article-title":"Forkhead class O transcription factor 3a activation and Sirtuin1 overexpression in the hypertrophied myocardium of the diabetic Goto-Kakizaki rat","volume":"26","author":"Vahtola","year":"2008","journal-title":"J Hypertens"},{"key":"R24-25-20210208","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.44.4.503","article-title":"Myocardial infarct size and ventricular function in rats.","volume":"44","author":"Pfeffer","year":"1979","journal-title":"Circ Res"},{"key":"R25-25-20210208","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.amjcard.2004.05.056","article-title":"Apoptotic cardiomyocyte death in fatal myocarditis","volume":"94","author":"Kyto","year":"2004","journal-title":"Am J Cardiol"},{"key":"R26-25-20210208","doi-asserted-by":"crossref","first-page":"H1775","DOI":"10.1152\/ajpheart.00305.2002","article-title":"Structural, functional, and molecular characterization of the SHHF model of heart failure","volume":"283","author":"Heyen","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R27-25-20210208","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.lungcan.2008.06.007","article-title":"Molecular analysis of the Ink4a\/Rb1-Arf\/Tp53 pathways in radon-induced rat lung tumors","volume":"63","author":"Bastide","year":"2009","journal-title":"Lung Cancer"},{"key":"R28-25-20210208","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1152\/physiolgenomics.00165.2004","article-title":"Cardiac gene expression profile in rats with terminal heart failure and cachexia","volume":"20","author":"Wellner","year":"2005","journal-title":"Physiol Genomics"},{"key":"R29-25-20210208","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.HYP.37.2.433","article-title":"Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats","volume":"37","author":"Cheng","year":"2001","journal-title":"Hypertension"},{"key":"R30-25-20210208","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejheart.2004.04.014","article-title":"Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure","volume":"6","author":"Cleland","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"R31-25-20210208","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ejheart.2007.10.002","article-title":"Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure","volume":"9","author":"Ikonomidis","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"R32-25-20210208","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10557-007-6066-7","article-title":"Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine","volume":"21","author":"Yilmaz","year":"2007","journal-title":"Cardiovasc Drugs Ther"},{"key":"R33-25-20210208","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1016\/j.atherosclerosis.2007.07.011","article-title":"Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure","volume":"195","author":"Parissis","year":"2007","journal-title":"Atherosclerosis"},{"key":"R34-25-20210208","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1161\/CIRCULATIONAHA.105.542407","article-title":"Mechanisms and use of calcium-sensitizing agents in the failing heart","volume":"113","author":"Kass","year":"2006","journal-title":"Circulation"},{"key":"R35-25-20210208","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.2165\/00003495-200363230-00009","article-title":"Levosimendan: a review of its use in the management of acute decompensated heart failure","volume":"63","author":"Innes","year":"2003","journal-title":"Drugs"},{"key":"R36-25-20210208","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.bcp.2004.05.018","article-title":"Potassium-specific effects of levosimendan on heart mitochondria","volume":"68","author":"Kopustinskiene","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"R37-25-20210208","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0014-2999(01)01350-4","article-title":"Levosimendan is a mitochondrial K(ATP) channel opener","volume":"428","author":"Kopustinskiene","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"R38-25-20210208","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(97)01108-4","article-title":"Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes","volume":"333","author":"Yokoshiki","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"R39-25-20210208","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0022-3565(24)36997-6","article-title":"The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells","volume":"283","author":"Yokoshiki","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R40-25-20210208","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejphar.2003.12.005","article-title":"The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig","volume":"486","author":"Szilagyi","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"R41-25-20210208","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2337\/diabetes.48.12.2463","article-title":"Pathophysiological and genetic characterization of the major diabetes locus in GK rats","volume":"48","author":"Galli","year":"1999","journal-title":"Diabetes"},{"key":"R42-25-20210208","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1046\/j.1523-1755.2003.00007.x","article-title":"Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy","volume":"63","author":"Janssen","year":"2003","journal-title":"Kidney Int"},{"key":"R43-25-20210208","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/01.hjh.0000179765.48324.b4","article-title":"Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats","volume":"23","author":"Cheng","year":"2005","journal-title":"J Hypertens"},{"key":"R44-25-20210208","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1053-0770(97)90252-4","article-title":"Effects of levosimendan on left ventricular function: correlation with plasma concentrations in conscious dogs","volume":"11","author":"McGough","year":"1997","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R45-25-20210208","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM199610173351603","article-title":"Apoptosis in myocytes in end-stage heart failure","volume":"335","author":"Narula","year":"1996","journal-title":"N Engl J Med"},{"key":"R46-25-20210208","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJM199704173361603","article-title":"Apoptosis in the failing human heart","volume":"336","author":"Olivetti","year":"1997","journal-title":"N Engl J Med"},{"key":"R47-25-20210208","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1161\/01.RES.86.11.1107","article-title":"Apoptosis and heart failure: a critical review of the literature","volume":"86","author":"Kang","year":"2000","journal-title":"Circ Res"},{"key":"R48-25-20210208","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000165128.39715.87","article-title":"Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure","volume":"111","author":"Ding","year":"2005","journal-title":"Circulation"},{"key":"R49-25-20210208","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1161\/hh1201.092094","article-title":"Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells","volume":"88","author":"Akao","year":"2001","journal-title":"Circ Res"},{"key":"R50-25-20210208","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/01.RES.0000247029.31997.a4","article-title":"Signaling mechanisms in ischemic preconditioning: interaction of PKCepsilon and MitoK(ATP) in the inner membrane of mitochondria","volume":"99","author":"Ardehali","year":"2006","journal-title":"Circ Res"},{"key":"R51-25-20210208","doi-asserted-by":"crossref","first-page":"H305","DOI":"10.1152\/ajpheart.2000.278.1.H305","article-title":"Ischemic preconditioning in rats: role of mitochondrial K(ATP) channel in preservation of mitochondrial function","volume":"278","author":"Fryer","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R52-25-20210208","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/ncpcardio1324","article-title":"Vascular aging: insights from studies on cellular senescence, stem cell aging, and progeroid syndromes","volume":"5","author":"Minamino","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"R53-25-20210208","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1172\/JCI22475","article-title":"Ink4a\/Arf expression is a biomarker of aging","volume":"114","author":"Krishnamurthy","year":"2004","journal-title":"J Clin Invest"},{"key":"R54-25-20210208","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/01.RES.0000093985.76901.AF","article-title":"Senescence and death of primitive cells and myocytes lead to premature cardiac aging and heart failure","volume":"93","author":"Chimenti","year":"2003","journal-title":"Circ Res"},{"key":"R55-25-20210208","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1161\/HYPERTENSIONAHA.107.099432","article-title":"Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a","volume":"52","author":"Westhoff","year":"2008","journal-title":"Hypertension"},{"key":"R56-25-20210208","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/ATVBAHA.108.164368","article-title":"Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells","volume":"28","author":"Ota","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004872-200910000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T21:49:52Z","timestamp":1739915392000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-200910000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e32832f0ce4","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}